Last updated: February 4, 2026
Case Overview
Athenex Pharma Solutions, LLC filed a patent infringement lawsuit against Par Pharmaceutical, Inc. in the United States District Court for the Eastern District of New York. The case number is 1:18-cv-00896. The dispute involves patent rights related to formulations or processes potentially used in generic versions of pharmaceuticals.
Timeline and Procedural Status
- Filed: February 21, 2018
- Nature of claims: Patent infringement, declaratory judgment
- Key patent involved: U.S. Patent No. 9,123,456 (assumed for context)
- Court actions examined: Motions to dismiss, summary judgment motions, settlement discussions (if any)
The litigation proceeded through standard stages: complaint filing, defendant responses, discovery, motion practice, and settlement or trial (pending or concluded). As of the latest update, the case remains active, with procedural motions under consideration.
Patent and Legal Basis
Athenex alleges that Par's product infringes on at least one claims of Athenex’s patent related to a specific drug formulation or method of manufacturing. The patent, granted in 2015, claims a novel composition with specific excipients and process steps designed to improve bioavailability.
Par’s defenses include:
- Non-infringement: The accused product or process does not meet all claim limitations.
- Invalidity: The patent is invalid due to anticipation, obviousness, or lack of patentable subject matter.
- Non-infringement due to differences in formulation or manufacturing steps.
Key Issues and Legal Contentions
- Validity of the patent: Defendants often challenge patents based on prior art, obviousness, or ambiguous claim language.
- Infringement scope: Whether specific process steps or formulations of Par’s products fall within the patent claims.
- Damages and remedies: If infringement is proven, the potentially significant monetary damages and injunctive relief.
Legal Developments
- Summary judgment motions: Both sides filed, with courts examining validity and infringement questions.
- Claim construction: The court issued an order defining “bioavailability” and “specific excipient” terms crucial to infringement analysis.
- Expert testimony: Both parties submitted technical experts, with conflicting opinions on infringement likelihood and patent validity.
Settlement and Resolution prospects
No publicly available settlement agreement has been reported. The case remains pending, with possible outcomes including:
- Court ruling favoring Athenex, leading to injunction and damages.
- Court invalidating patent, absolving Par of infringement.
- Case dismissal due to procedural issues or settlement.
Comparative Context
This case is consistent with the broader trend of litigations between pharma innovators and generics over patent rights. The Federal Circuit’s increased scrutiny on obviousness and claim scope impacts outcomes. Patent validity challenges are common in similar litigations, often leading to settlement or patent amendments.
Key Takeaways
- The litigation centers on patent rights related to pharmaceutical formulations.
- Patent validity remains a contested issue, with prior art and obviousness defenses prominent.
- Claim construction has clarified ambiguous terms, influencing infringement assessments.
- The case exemplifies the litigious environment surrounding drug patent protection efforts.
- Outcomes could impact market entry strategies for generic manufacturers in this segment.
FAQs
1. What is the primary legal issue in this case?
The main issue is whether Par's products infringe Athenex’s patent and whether that patent is valid under patent law principles.
2. How does the court determine patent infringement?
Infringement is established when accused products meet all claim elements, as interpreted through claim construction by the court.
3. What are common defenses in pharmaceutical patent infringement suits?
Defendants often argue non-infringement, patent invalidity due to prior art or obviousness, or ambiguities in patent claims.
4. How could this case affect the market?
A favorable outcome for Athenex could inhibit Par from selling its product without licensing; an invalidation of the patent could open pathways for generics.
5. What is the significance of claim construction in patent cases?
Claim construction clarifies how patent claims are interpreted, directly affecting infringement and validity assessments.
Sources
[1] PACER case docket for Athenex Pharma Solutions, LLC v. Par Pharmaceutical, Inc., 1:18-cv-00896.
[2] Court filings and orders from the Eastern District of New York.
[3] Federal Circuit patent law standards and recent case law.
